Researchers analyze prostate cancer incidence over 20 years in men aged 45-70 years without prostate cancer and identify ...

A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in ...

In patients with elevated PSA, the urinary MPS2 test had high accuracy for ruling out high-grade prostate cancer requiring biopsy. The urinary 18-gene MyProstateScore 2.0 (MPS2) test can detect ...

For prostate biopsy planning, multiparametric MRI has relatively low specificity particularly for PI-RADS 3 and PI-RADS 4 ...

An artificial intelligence system slightly outperformed radiologists using PI-RADS at detecting clinically significant prostate cancer. A trained artificial intelligence (AI) system discriminated ...

The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...

A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate ...

Many men with low levels could be spared from invasive procedures and frequent testing ...

New evidence compares micro-ultrasound and MRI fusion biopsy for detecting clinically significant prostate cancer. Find out ...

A recent study from researchers at Vanderbilt University and the University of Michigan has demonstrated that a simple ...

Akeega, an oral dual mechanism therapy pairing niraparib with abiraterone, has won a positive committee opinion in Europe for ...